Cargando…
FGFR3 overactivation in the brain is responsible for memory impairments in Crouzon syndrome mouse model
Crouzon syndrome with acanthosis nigricans (CAN, a rare type of craniosynostosis characterized by premature suture fusion and neurological impairments) has been linked to a gain-of-function mutation (p.Ala391Glu) in fibroblast growth factor receptor 3 (FGFR3). To characterize the CAN mutation’s impa...
Autores principales: | Cornille, Maxence, Moriceau, Stéphanie, Khonsari, Roman H., Heuzé, Yann, Loisay, Léa, Boitez, Valérie, Morice, Anne, Arnaud, Eric, Collet, Corinne, Bensidhoum, Morad, Kaci, Nabil, Boddaert, Nathalie, Paternoster, Giovanna, Rauschendorfer, Theresa, Werner, Sabine, Mansour, Suzanne L., Di Rocco, Federico, Oury, Franck, Legeai-Mallet, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906494/ https://www.ncbi.nlm.nih.gov/pubmed/35254402 http://dx.doi.org/10.1084/jem.20201879 |
Ejemplares similares
-
Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022) -
Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice
por: Loisay, Léa, et al.
Publicado: (2023) -
FGFR3 in Periosteal Cells Drives Cartilage-to-Bone Transformation in Bone Repair
por: Julien, Anais, et al.
Publicado: (2020) -
OR21-05 Low-dose Infigratinib, An Oral Selective Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, Demonstrates Activity In Murine Models Of Achondroplasia And Hypochondroplasia
por: Muslimova, Elena, et al.
Publicado: (2023) -
PMON30 Low-dose Infigratinib, an Oral Selective Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor, Demonstrates Activity in a Preclinical Model of Hypochondroplasia
por: Dambkowski, Carl, et al.
Publicado: (2022)